drugset / Trial / NCT05177276
Selinexor Combination Ph 1 Study
Phase 1/2
Withdrawn
Martin Gutierrez
Hackensack Meridian Health · collabKaryopharm Therapeutics Inc · collab
Non-randomizedSequentialOpen-labelBasic science
Summary
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of selinexor (KPT-330) in combination with Irinotecan in patients with solid tumors. A secondary purpose is to evaluate the pharmacokinetics (PK) of selinexor with irinotecan.
Timeline
- Start
- 2014-09
- Primary completion
- 2015-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Selinexor | Other / unclassified | 12 mg | Oral |
| Subject | Selinexor | Other / unclassified | 15 mg | Oral |
| Subject | Selinexor | Other / unclassified | 20 mg | Oral |
| Subject | Selinexor | Other / unclassified | 30 mg | Oral |